Long-term exposure to lifelong therapies

Journal of Acquired Immune Deficiency Syndromes

Volumn 29, Issue SUPPL. 1, 2002, Pages

  Powderly, William G ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretroviral therapy; Lactic acidemia; Lactic acidosis; Lipodystrophy

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; ATORVASTATIN; DIDANOSINE; NEVIRAPINE; NUCLEOSIDE DERIVATIVE; PRAVASTATIN; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SIMVASTATIN; STAVUDINE; TROGLITAZONE;

ACIDOSIS; AVASCULAR NECROSIS; BONE DISEASE; BONE METABOLISM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL DAMAGE; DIABETES MELLITUS; DRUG EFFECT; DRUG TOXICITY; DYSLIPIDEMIA; FATTY LIVER; GLUCOSE METABOLISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; INSULIN RESISTANCE; LIPOATROPHY; LIPODYSTROPHY; LONG TERM CARE; LONG TERM EXPOSURE; METABOLIC DISORDER; MITOCHONDRION; MYOPATHY; NEUROPATHY; OSTEOPENIA; OSTEOPOROSIS; PANCREATITIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

EID: 0036470917     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200202011-00005     Document Type: Review

References (67)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
2. Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway
3. Riboflavin to treat nucleoside analogue-induced lactic acidosis
4. Steatosis-lactic acidosis syndrome associated with stavudine and lamivudine therapy
5. Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy
6. Zidovudine-induced fatal lactic acidosis and hepatic failure in patients with acquired immunodeficiency syndrome: Report of two patients and review of the literature
7. Lactic acidosis. A new insight?
8. Hepatic steatosis and lactic acidosis caused by stavudine in an HIV-infected patient
9. Lactic acidosis and hepatic steatosis associated with use of stavudine: Report of four cases
10. Lactic acidosis associated with stavudine administration: A report of five cases
11. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity
12. Sodium bicarbonate for the treatment of lactic acidosis
13. Riboflavin and severe lactic acidosis
14. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: Contribution to protease inhibitor-related lipodystrophy syndrome
15. Hyperlactatemia and antiretroviral therapy: The Swiss HIV Cohort Study
16. Lactate concentrations distinguish between nucleoside neuropathy and HIV distal symmetrical sensory polyneuropathy
17. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: A 5-year cohort study
18. HIV-associated lipodystrophy syndrome
19. Lipodystrophy associated with an HIV-protease inhibitor
20. Lipodystrophy in patients naive to HIV protease inhibitors
21. Incidence of fat tissue abnormalities in protease inhibitor-naive patients treated with NRTI combinations
22. Lipodystrophies
23. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection
24. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving longterm nucleoside analogue therapy
25. The Australian lipodystrophy prevalence survey
26. Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy
27. Highly active antiretroviral therapy and coronary heart disease: The need for perspective
28. Impact of treatment with protease inhibitor (PI) on myocardial infarction (MI) occurrence in HIV-infected men
29. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors
30. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection
31. Insulin resistance in HIV protease inhibitor-associated diabetes
32. HIV-protease inhibitor switch to nevirapine improves insulin tolerance but does not correct adipose tissue maldistribution
33. A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat redistribution
34. Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine
35. The effects of polylactic acid as therapy for lipoatrophy of the face
36. The strategy of antiretroviral switch studies - A review
37. Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial
38. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes
39. Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy
40. Nevirapinecontaining antiretroviral therapy in HIV-1-infected patients in an anti-atherogenic lipid profile
41. Review of NNRTIs: "Today and tomorrow."
42. Impact of switching from human immunodeficiency virus type 1 protease inhibitors to efavirenz in successfully treated adults with lipodystrophy
43. Switching protease inhibitor (PI) to nevirapine (NVP) leads to a better lipid profile than switch to efavirenz (EFV)
44. Do protease inhibitors increase the risk for coronary heart disease among HIV positive patients - Follow-up through June 2000 [abstract 655]
45. Disorders of glucose metabolism in patients infected with human immunodeficiency virus
46. A randomised, double-blind study of gemfibrozil (GF) for the treatment of protease inhibitorassociated hypertriglyceridaemia
47. Pharmacokinetic interactions between protease inhibitors and selected HMG-CoA reductase inhibitors [abstract LB6]
48. The mechanism of insulin resistance caused by HIV protease inhibitor therapy
49. Glucose disorders associated with HIV and its drug therapy
50. Safety profile and tolerability of amprenavir in the treatment of adult and pediatric patients with HIV infection
51. Hyperglycemia associated with protease inhibitors in an urban HIV-infected minority population
52. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients
53. Improvement of HAART-associated insulin resistance and dyslipidemia after replacement of protease inhibitors with abacavir
54. Prevalence of lipodystrophy and metabolic abnormalities in the Multicenter AIDS Cohort Study (MACS)
55. Stavudine versus zidovudine and the development of lipodystrophy
56. A randomised trial of thymidine analogue withdrawal in lipotrophic HIV patients, virologically controlled on protease sparing therapy - The PIILR extension study
57. Clinical and laboratory characteristics of lipodystrophy in a French cohort of HIV-infected patients treated with protease inhibitors
58. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy
59. Osteopenia in a randomized, multicentre study of protease inhibitor substitution in patients with the lipodystrophy syndrome-extended follow-up to 48 weeks
60. Bone abnormalities in HIV-infected patients on HAART
61. Indinavir inhibits bone formation while ritonavir inhibits osteoclast differentiation and function
62. Osteopenia in HIV-infected men: Association with a symptomatic lactic acidemia and lowerweight pre-antiretroviral therapy
63. High prevalence of avascular necrosis (AVN) of the hip in HIV infection: Magnetic resonance imaging of 339 asymptomatic patients
64. Osteonecrosis in patients infected with human immunodeficiency virus: A case-control study
65. Osteonecrosis in HIV: A case-control study